Reply to: “Rethinking Treatment Priorities in Estrogen Receptor–Low Breast Cancer” and “CDK4/6 Inhibitors in Estrogen Receptor–Low Breast Cancer”

Matthew P. Goetz; Grace M. Choong; Tanya L. Hoskin; Judy C. Boughey; Sameera R. Wijayawardana; James N. Ingle

doi:10.1200/jco-25-01688

Reply to: “Rethinking Treatment Priorities in Estrogen Receptor–Low Breast Cancer” and “CDK4/6 Inhibitors in Estrogen Receptor–Low Breast Cancer”

M Matthew P. Goetz G Grace M. Choong (Mayo Clinic, Rochester, MN) T Tanya L. Hoskin (Mayo Clinic Rochester, Rochester, MN) J Judy C. Boughey (Matthew P. Goetz, MD and Grace M. Choong, MD, Department of Oncology, Mayo Clinic, Rochester, MN; Tanya L. Hoskin, MS, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN; Judy C. Boughey, MD, Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN; Sameera R. Wijayawardana, PhD, Eli Lilly and Company, Indianapolis, IN; and James N. Ingle, MD, Department of Oncology, Mayo Clinic, Rochester, MN) S Sameera R. Wijayawardana (Matthew P. Goetz, MD and Grace M. Choong, MD, Department of Oncology, Mayo Clinic, Rochester, MN; Tanya L. Hoskin, MS, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN; Judy C. Boughey, MD, Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN; Sameera R. Wijayawardana, PhD, Eli Lilly and Company, Indianapolis, IN; and James N. Ingle, MD, Department of Oncology, Mayo Clinic, Rochester, MN) J James N. Ingle (Mayo Clinic Rochester, Rochester, MN)

View Original

APA MLA Chicago BibTeX RIS

Article Details

Journal Journal of Clinical Oncology

Volume / Issue Vol. 43, Issue 30

Published October 20, 2025

Pages 3323-3324

DOI 10.1200/jco-25-01688

ISSN 0732-183X

Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (6)

M

Matthew P. Goetz

G

Grace M. Choong

Mayo Clinic, Rochester, MN

T

Tanya L. Hoskin

Mayo Clinic Rochester, Rochester, MN

J

Judy C. Boughey

Matthew P. Goetz, MD and Grace M. Choong, MD, Department of Oncology, Mayo Clinic, Rochester, MN; Tanya L. Hoskin, MS, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN; Judy C. Boughey, MD, Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN; Sameera R. Wijayawardana, PhD, Eli Lilly and Company, Indianapolis, IN; and James N. Ingle, MD, Department of Oncology, Mayo Clinic, Rochester, MN

S

Sameera R. Wijayawardana

Matthew P. Goetz, MD and Grace M. Choong, MD, Department of Oncology, Mayo Clinic, Rochester, MN; Tanya L. Hoskin, MS, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN; Judy C. Boughey, MD, Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN; Sameera R. Wijayawardana, PhD, Eli Lilly and Company, Indianapolis, IN; and James N. Ingle, MD, Department of Oncology, Mayo Clinic, Rochester, MN

J

James N. Ingle

Mayo Clinic Rochester, Rochester, MN

Reply to: “Rethinking Treatment Priorities in Estrogen Receptor–Low Breast Cancer” and “CDK4/6 Inhibitors in Estrogen Receptor–Low Breast Cancer”

Article Details

Journal Info

Authors (6)

Related Articles from this Journal

Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)

Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer